Drug Trial Radar · NCT07586943
SKB118 Injection in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
530
Planned (sponsor's estimate)
Start
Jun 1, 2026
Primary completion
Dec 2029
Study completion Dec 2030
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase I/II clinical study. The study is divided into two parts, the SKB118 monotherapy study and the SKB118 in combination with SKB264 study.
Conditions
- Advanced Solid Tumors
Interventions
SKB118 InjectionDrug
SKB118 Injection monotherapy, iv drip, every 3 weeks (Q3W), until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.
SKB118+SKB264Drug
Administered by intravenous infusion on Day 1 and Day 15 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects achieving Dose-limiting toxicity (DLT)Time frame: From date of initial dose until up to 21 days after the first dose for q3w dosing frequency; or up to 28 days after the first dose for q2w dosing frequency
- Objective response rate (ORR)Time frame: Up to approximately 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.